Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 1.00 |
| ▸ | CES1 | P23141 | 4/20 | 1.00 |
| ▸ | FAAH2 | Q6GMR7 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3183288 | 1.00 | FAAH (1.00) | FAAHCES1FAAH2 | |
| SCHEMBL3203964 | 1.00 | FAAH (1.00) | FAAHCES1FAAH2 | |
| SCHEMBL3193713 | 1.00 | FAAH (1.00) | FAAHCES1FAAH2 | |
| SCHEMBL3196450 | 0.99 | FAAH (0.98) | FAAHCES1FAAH2 | |
| SCHEMBL3184217 | 0.95 | FAAH (0.91) | FAAHCES1FAAH2 | |
| SCHEMBL712398 | 0.92 | FAAH (0.85) | FAAHCES1FAAH2 | |
| SCHEMBL710374 | 0.91 | FAAH (0.83) | FAAHCES1FAAH2 | |
| SCHEMBL720053 | 0.91 | FAAH (0.83) | FAAHCES1FAAH2 | |
| SCHEMBL719614 | 0.91 | FAAH (0.83) | FAAHCES1FAAH2 | |
| SCHEMBL710756 | 0.91 | FAAH (0.83) | FAAHCES1FAAH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024225481-A1 | AGENT FOR IMPROVING THERAPEUTIC RESPONSIVENESS IN CANCER IMMUNOTHERAPY WITH PD-1 INHIBITOR OR PD-L1 INHIBITOR | 国立大学法人京都大学 | 2024-10-31 | — | — | WO | claimed |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2026-04-16 | — | — | US | disclosed |
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| US-12421281-B2 | Cyclosporine compositions and methods of use | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-09-23 | — | — | US | disclosed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-20250205175-A1 | Anti-Aging Composition with mTOR inhibitor for Humans and Other Mammals | POSTREL RICHARD (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250179121-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-06-05 | — | — | US | disclosed |
| US-20250152562-A1 | Compositions to Enhance and Extend Quality of Life | POSTREL RICHARD (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2025085674-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ULCERATIVE COLITIS | BACAINN THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12280019-B2 | Anti-aging therapy for humans and other mammals | POSTREL RICHARD (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2007098142-A2 | OXAZOLE KETONES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007098142-A2 | OXAZOLE KETONES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007061862-A2 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007005510-A1 | N-HETEROARYLPIPERAZINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004741-A1 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | APODACA RICHARD | 2007-01-04 | — | — | US | disclosed |
| US-20070004741-A1 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | APODACA RICHARD | 2007-01-04 | — | — | US | disclosed |
| EP-1549624-A4 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | SCRIPPS RESEARCH INST (US) | 2006-09-20 | — | — | EP | disclosed |
| US-20060111359-A1 | enzyme inhibitor for treating sleep disorders | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-05-25 | — | — | US | disclosed |
| EP-1549624-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | The Scripps Research Institute (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004033652-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | ABCC1, SLC47A2, ABCB1 | FAAH 2184/4885CES1 1382/4885FAAH2 1345/4885 |
| US-20060111359-A1 | enzyme inhibitor for treating sleep disorders | FAAH, FAAH2, HCRTR2 | FAAH 1/4885CES1 12/4885FAAH2 2/4885 |
| US-12421281-B2 | Cyclosporine compositions and methods of use | FPR2, FPR1, FPR3 | FAAH 2000/4885CES1 940/4885FAAH2 898/4885 |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | MGLL, PNLIP, LPL | FAAH 12/4885CES1 46/4885FAAH2 23/4885 |
| US-20250179121-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | FPR2, FPR1, FPR3 | FAAH 1629/4885CES1 470/4885FAAH2 816/4885 |
| US-20070004741-A1 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | FAAH, FAAH2, CNR2 | FAAH 1/4885CES1 208/4885FAAH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.